Estrogen/EGF receptor interactions in breast cancer: Rationale for new therapeutic combination strategies

Biomedicine and Pharmacotherapy

Volumn 57, Issue 10, 2003, Pages 447-451

  Lichtner, Rosemarie B ^a  

^a NONE   (Germany)

Author keywords

Cross talk; EGF receptor; Endocrine resistance; Estrogen receptor

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; GEFITINIB; LETROZOLE; TAMOXIFEN; TRASTUZUMAB;

ANGIOGENESIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE COURSE; HORMONAL THERAPY; HORMONE RESISTANCE; HORMONE RESPONSE; HUMAN; LIGAND BINDING; META ANALYSIS; METASTASIS; MOLECULAR INTERACTION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR RECURRENCE;

EID: 0345306247     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2003.09.006     Document Type: Article

References (50)

1. Adjel A.A. Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy. Drugs Future. 26:2001;1087-1092.
2. Archer S.G., Eliopoulos A., Spandidos D., et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer. 72:1995;1259-1266.
3. Arteaga C.L., Ramsey T.T., Shawer L.K., Guyer C.A. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J Biol Chem. 272:1997;23247-23254.
4. Bates S.E., Davidson N.E., Valverius E.M., Freter C.E., Dickson R.B., Tam J.P., et al. Expression of transforming growth factor-α and its messenger RNA in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol. 2:1988;543-555.
5. Bonneterre J., Thurlimann B., Robertson J.F., Krzakowski M., Mauriac L., Koralewski P., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 18:2000;3748-3757.
6. Buteau-Lozano H., Ancelin M., Lardeux B., Milanini J., Perrot-Applanat M. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors α and &beta. Cancer Res. 62:2002;4977-4984.
7. Ciardiello F., Caputo R., Bianco R., et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res. 7:2001;1459-1465.
8. Chrysogelos S.A., Yarden R.I., Lauber A.H., Murphy J.M. Mechanisms of EGF receptor regulation in breast cancer cells. Breast Cancer Res Treat. 31:1994;227-236.
9. Clarke R., Leonessa F., Welch J.N., Skaar T.C. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev. 53:2001;25-71.
10. Dauvois S., Daniellan P.S., White R., Parker M.G. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA. 89:1992;4037-4041.
11. Davidson N.E., Gelmann E.P., Lippman M.E., Dickson R.B. Epidermal growth factor receptor gene expression in estrogen positive and negative human breast cancer cell lines. Mol Endocrinol. 1:1987;216-223.
12. DeFazio A., Chiew Y.-E., Donoghue C., Lee C.S.L., Sutherland R.L. Effect of sodium butyrate on estrogen receptor and epidermal growth factor receptor gene expression in human breast cancer cell lines. J Biol Chem. 267:1992;18008-18012.
13. DeFazio A., Chiew Y.-E., McEvoy M., Watts C.K.W., Sutherland R.L. Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells. Cell Growth Differ. 8:1997;903-911.
14. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
15. Howell A., DeFriend D., Robertson J., Blamey R., Walton P. Response to a specific antioestrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet. 345:1995;29-30.
16. Khazaie K., Schirrmacher V., Lichtner R.B. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev. 12:1993;255-274.
17. Klijn J.G.M., Berns P.M.J.J., Schmitz P.I.M., Foekens J.A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev. 13:1992;3-17.
18. Kurokawa H., Arteaga C.L. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res. 9:2003;511S-515S.
19. Lee C.S.L., Koga M., Sutherland R.L. Modulation of estrogen receptor and epidermal growth factor receptor mRNA by phorbol ester in MCF-7 breast cancer cells. Biochem Biophys Res Commun. 162:1989;415-421.
20. Lee A.V., Schiff R., Cui X., Sachdev D., Yee D., Gilmore A.P., et al. New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation. Clin Cancer Res. 9:2003;516S-523S.
21. Martinez-Lacaci I., Secada M., Plowman G., Johnson G., Normanno N., Salomon D.S., et al. Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines. Endocrinology. 136:1995;3983-3992.
22. McLelland R.A., Barrow D., Madden T.A., et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology. 142:2001;2776-2788.
23. Migliaccio A., Di Domenico M., Castoria G., de Falco A., Bontempo P., Nola E., et al. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF7 cells. EMBO J. 15:1996;1292-1300.
24. Miller D.L., El-Ashry D., Cheville A.L., Liu Y., McLeskey S.W., Kern F.G. Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. Cell Growth Differ. 5:1994;1263-1274.
25. Moasser M.M., Basso A., Averbuch S.D., Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER-2-overexpressing tumor cells. Cancer Res. 61:2001;7184-7188.
26. Morris C. The role of EGFR-directed therapy in the treatment of breast cancer. Breast Cancer Res Treat. 75:2002;S51-S55.
27. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 19:2001;2596-2606.
28. Nabholtz J.M., Buzdar A., Pollak M., Harwin W., Burton G., Mangalik A., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 18:2000;3758-3767.
29. Newby J.C., Johnston S.R.D., Smith I.E., Dowsett M. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res. 3:1997;1643-1651.
30. Nicholson R.I., McClelland R.A., Gee J.M.W., et al. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat. 29:1994;117-125.
31. Nicholson R.I., Gee J.M.W. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer. 82:2000;501-505.
32. Nicholson R.I., Hutcheson I.R., Harper M.E., Knowlden J.M., Barrow D., McClelland R.A., et al. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr-Relat Cancer. 8:2001;175-182.
33. Osborne C.K. Tamoxifen in the treatment of breast cancer. New Engl J Med. 339:1998;1609-1618.
34. Perrotte P., Matsumoto T., Inoue K., Kuniyasu H., Eve B.Y., Hicklin D.J., et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 5:1999;257-265.
35. Robertson J.F.R. Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer. 73:1996;5-12.
36. Russo S.M., Ove R. Molecular targets as therapeutic strategies in the management of breast cancer. Expert Opin Ther Targets. 7:2003;543-557.
37. Schiff R., Massaeweh S., Shou J., Osborne C.K. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res. 9:2003;447S-454S.
38. Schmidt M., Lichtner R.B. EGF receptor targeting in therapy-resistant human tumors. Drug Resist Updates. 5:2002;11-18.
39. Secada M., Knabbe C., Dickson R.B., Lippman M.E., Bronzert D., Lindsey R.K., et al. Post-transcriptional destabilization of estrogen receptor mRNA in MCF-7 cells by 12-O-tetradecanoylphorbol-13 acetate. J Biol Chem. 266:1991;17809-17814.
40. Sharma A.K., Horgan K., Douglas-Jones A., McClelland R., Gee J., Nicholson R. Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer. Br J Cancer. 69:1994;1032-1037.
41. Sharma A.K., Grimshaw D., Horgan K., Neades G.T., Gee J.M.W., Douglas-Jones A.G., et al. Analysis of the genes for oestrogen and epidermal growth factor receptors in human breast cancer. Breast. 5:1996;344-350.
42. Sharma A.K., Grimshaw D., Horgan K., Douglas-Jones A., Mansel R., Gee J., et al. Investigation of the mechanisms determining the inverse relationship between oestrogen and epidermal growth factor receptors in primary human breast cancer. Breast. 6:1997;371-378.
43. Sommer A., Hoffmann J., Lichtner R.B., Schneider M.R., Parczyk K. Studies on the development of resistance to the pure antiestrogen Faslodex™ in three human breast cancer cell lines. J Steroid Biochem Mol Biol. 85:2003;33-47.
44. Speirs V., Malone C., Walton D.S., Kerin M.J., Atkin S.L. Increased expression of estrogen receptor ß mRNA in tamoxifen-resistant breast cancer patients. Cancer Res. 59:1999;5421-5424.
45. Toledo L.M., Lydon N.B., Elbaum D. The structure-based design of ATP-site directed protein kinase inhibitors. Curr Med Chem. 6:1999;775-805.
46. van Agthoven T.T., van Agthoven T.L., Portengen H., Foekens J.A., Dorssers L.C. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res. 52:1992;5082-5088.
47. van Agthoven T., Timmermans M., Foekens J.A., Dorssers L.C.J., Henzen-Logmans S.C. American differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry. J Pathol. 244:1994;1238-1246.
48. Yang X.D., Jia X.C., Corvalan J.R., Wang P., Davis C.G., Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomittant chemotherapy. Cancer Res. 59:1999;1236-1243.
49. Yarden R.I., Wilson M.A., Chrysogelos S.A. Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J Cell Biochem Suppl. 36:2001;232-246.
50. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2:2001;127-137.